Tamoxifen--the treatment of choice. Why look for alternatives?
Open Access
- 1 January 1998
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 78 (4) , 1-4
- https://doi.org/10.1038/bjc.1998.753
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Five Versus More Than Five Years of Tamoxifen Therapy for Breast Cancer Patients With Negative Lymph Nodes and Estrogen Receptor-Positive TumorsJNCI Journal of the National Cancer Institute, 1996
- Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.Journal of Clinical Oncology, 1996
- Tamoxifen-associated eye disease. A review.Journal of Clinical Oncology, 1996
- A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancerEuropean Journal Of Cancer, 1995
- Changes in incidence of and mortality from breast cancer in England and Wales since introduction of screeningBMJ, 1995
- Use of tamoxifen for breast cancer: twenty-eight years later.Journal of Clinical Oncology, 1995
- Effects of Tamoxifen on Cardiovascular Risk Factors in Postmenopausal Women After 5 Years of TreatmentJNCI Journal of the National Cancer Institute, 1994
- Long term effects of tamoxifen on blood lipid values in breast cancer.BMJ, 1992
- Effects of Tamoxifen on Bone Mineral Density in Postmenopausal Women with Breast CancerNew England Journal of Medicine, 1992
- Endocrine therapy for advanced breast cancer: A reviewBreast Cancer Research and Treatment, 1992